A5101433240- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Plant Molecular Biology Research
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Gastrointestinal Tumor Research and Treatment
- Neuroscience of respiration and sleep
- Autoimmune and Inflammatory Disorders Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- Glycosylation and Glycoproteins Research
- Nausea and vomiting management
- Parvovirus B19 Infection Studies
- Clinical Nutrition and Gastroenterology
- Mycobacterium research and diagnosis
- Dysphagia Assessment and Management
- Polyomavirus and related diseases
- Transplantation: Methods and Outcomes
Sichuan University
2016-2025
West China Hospital of Sichuan University
2016-2025
Jiangsu Province Hospital
2021-2025
Nanjing Medical University
2017-2025
Beijing Children’s Hospital
2023-2024
Capital Medical University
2023-2024
Center for Children
2024
Qiqihar University
2024
Southeast University
2024
University of Shanghai for Science and Technology
2023
Abstract Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse poor, and treatment choices are limited. We evaluated the efficacy safety of zanubrutinib, investigational selective Bruton's tyrosine kinase (BTK) inhibitor. Patients Methods: relapsed/refractory MCL were enrolled in this ongoing phase II, single-arm, open-label study, treated oral zanubrutinib...
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, approved patients with MCL who have received ≥1 prior therapy. We report the long-term safety and efficacy results from multicenter, open-label, phase 2 registration trial of zanubrutinib. Patients (n = 86) oral zanubrutinib 160 mg twice daily. The primary endpoint was overall response rate (ORR), assessed per Lugano...
Various studies have highlighted the important associations between obstructive sleep apnea (OSA) and gut microbiota related metabolites. Nevertheless, establishment of causal relationships these remains to be determined. Multiple mendelian randomization (MR) analyses were performed genetically predict causative impact 196 83 metabolites on OSA. Two-sample MR was used assess potential association, causality evaluated using inverse variance weighted (IVW), MR-Egger, median (WM) methods....
Rosacea is a common chronic inflammatory disorder primarily affecting the face. While factors are known to play pivotal role in its pathogenesis, their causal relationship with rosacea remains unclear. This study employed two-sample bidirectional Mendelian randomization (MR) analysis investigate links between systemic regulators and rosacea. Data on 41 cytokines growth were analyzed from genome-wide association (GWAS) meta-analysis involving 8293 individuals genetic data FinnGen database,...
Previous studies highlight the need for a more active conditioning therapy in high-risk or refractory and relapsed lymphomas. Our preclinical research shows that histone deacetylase inhibitors, such as either vorinostat chidamide, sensitize lymphoma cells to cytotoxic combination of cladribine, gemcitabine busulfan, leading cell apoptosis. To evaluate efficacy this chidamide-cladribine-gemcitabine-busulfan (ChiCGB) new therapy, we conducted Phase II trial, described here. Patients with...
Abstract Patients with relapsed/refractory (R/R) mature T- and natural killer (NK)–cell neoplasms lack effective treatments after failure of standard therapies. This phase 2 study evaluated the efficacy safety programmed cell death protein 1 inhibitor tislelizumab in these patients. Seventy-seven patients were treated 200 mg every 3 weeks. Twenty-two extranodal NK-/T-cell lymphomas enrolled cohort 1; 44 peripheral T-cell lymphoma (PTCL) (21 had PTCL not otherwise specified, 11...
Obstructive sleep apnoea (OSA) is a sleep-disordered breathing characterized by intermittent hypoxia (IH) that may cause cognitive dysfunction. However, the impact of IH on molecular processes involved in function remains unclear. C57BL / 6 J mice were exposed to either normoxia (control) or for weeks. DNA hydroxymethylation was quantified hydroxymethylated immunoprecipitation (hMeDIP) sequencing. ten-eleven translocation 1 (Tet1) knocked down lentivirus. Specifically, assessed behavioral...
Abstract Background Myeloid sarcoma (MS) is a rare, extramedullary tumor consisting of myeloid blasts. Little known about the genetic background MS and prognostic value abnormalities in MS. In particular, broad variety gene fusions that occur marginally covered by traditional testing methods due to lack fresh specimens. Methods Here, we analyzed clinical features 61 cases. We performed RNA sequencing (RNA‐seq) on formalin‐fixed paraffin‐embedded (FFPE) or samples analyze fusion genes 26...
Abstract Acute promyelocytic leukemia (APL) is generally driven by PML::RARA , but approximately 2% of variant APL patients do not contain this fusion gene and pose challenges in diagnosis treatment. Here, we reported an aggressive patient with TNRC18::RARA gene, who was resistant to standard differentiation induction therapy consisting all‐trans retinoic acid (ATRA) arsenic trioxide achieved complete remission venetoclax plus ATRA. Mechanistically, possesses synergistic effects ATRA‐induced...
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic transplantation (allo-HSCT) the only curable treatment. The outcomes after transplant are influenced by both disease characteristics patient comorbidities. To develop novel prognostic model to predict post-transplant survival of CMML patients, we identified risk factors applying univariable multivariable Cox proportional hazards regression derivation cohort. In analysis, advanced age (hazard...
Abstract Background We previously reported results of a pooled analysis two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when is used second‐line versus later‐line. Here, we present an updated with longer follow‐up 35.2 months. Methods Data were from studies—BGB‐3111‐AU‐003 (NCT02343120) and BGB‐3111‐206 (NCT03206970) R/R MCL. The patients divided into groups based on the treatment line zanubrutinib: later‐line group. inverse propensity score...
The therapeutic status of allogeneic stem cell transplantation (allo-SCT) as a post-remission treatment for patients with high-risk acute myeloid leukemia (AML) was well-accepted. However, the optimal low/favorable- or intermediate-risk AML who achieve complete remission has remained controversial. Therefore, we conducted network meta-analysis to discuss this disputed problem.
We report the clinical results of sustainedly integrating imatinib and interferon-α into maintenance therapy in patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Maintenance lasted 5 years with 400 mg daily, 3 million units, 2∼3 doses per week, chemotherapy including vindesine dexamethasone scheduled monthly first year, once every 2 months second third year. The was discontinued after continued another years. For 41 without allo-HSCT a median follow-up...
7552 Background: Effective treatment choices for patients (pts) with relapsed/refractory (R/R) mature T/NK-cell neoplasms after failure of standard therapies are limited. Tislelizumab (TIS), a humanized anti-PD-1 mAb, demonstrated outstanding efficacy and favorable safety in pts R/R classical Hodgkin lymphoma or solid tumors. We present the phase 2 study TIS neoplasms. Methods: Pts were enrolled into 3 cohorts stratified by type neoplasm to receive 200 mg intravenously every weeks until...